| Primary |
| Drug Use For Unknown Indication |
37.5% |
| Pneumonia |
8.9% |
| Infection Prophylaxis |
5.4% |
| Pyrexia |
5.4% |
| Acute Lymphocytic Leukaemia |
3.6% |
| Breast Cancer |
3.6% |
| Hepatitis B |
3.6% |
| Idiopathic Pulmonary Fibrosis |
3.6% |
| Prophylaxis Against Graft Versus Host Disease |
3.6% |
| Stem Cell Transplant |
3.6% |
| Unevaluable Event |
3.6% |
| Viral Haemorrhagic Cystitis |
3.6% |
| Acute Graft Versus Host Disease |
1.8% |
| Adenoviral Haemorrhagic Cystitis |
1.8% |
| Atrial Fibrillation |
1.8% |
| Cystitis |
1.8% |
| Diarrhoea |
1.8% |
| Gastric Ulcer |
1.8% |
| Hepatic Function Abnormal |
1.8% |
| Renal Abscess |
1.8% |
|
| Haemolytic Anaemia |
22.2% |
| Pyrexia |
16.7% |
| Sepsis |
11.1% |
| Urticaria |
11.1% |
| Haemorrhage |
5.6% |
| Hallucination, Visual |
5.6% |
| Hypokalaemia |
5.6% |
| International Normalised Ratio Increased |
5.6% |
| Oral Mucosa Erosion |
5.6% |
| Renal Disorder |
5.6% |
| Respiratory Failure |
5.6% |
|
| Secondary |
| Pneumonia |
13.9% |
| Drug Use For Unknown Indication |
10.9% |
| Hypertension |
8.7% |
| Post Procedural Infection |
8.7% |
| Prostate Cancer |
7.0% |
| Pyrexia |
7.0% |
| Pneumonia Legionella |
6.5% |
| Prophylaxis |
6.5% |
| Biopsy Prostate |
6.1% |
| Antifungal Prophylaxis |
3.5% |
| Atrial Fibrillation |
2.6% |
| Gastritis |
2.6% |
| Peripheral T-cell Lymphoma Unspecified |
2.6% |
| Sepsis |
2.6% |
| Diabetes Mellitus |
2.2% |
| Back Pain |
1.7% |
| Benign Prostatic Hyperplasia |
1.7% |
| Herpes Zoster |
1.7% |
| Neutrophil Count Decreased |
1.7% |
| Product Used For Unknown Indication |
1.7% |
|
| Purpura |
12.0% |
| Toxic Epidermal Necrolysis |
10.0% |
| Liver Disorder |
8.0% |
| Urticaria |
8.0% |
| White Blood Cell Count Decreased |
8.0% |
| Renal Failure |
6.0% |
| Rhabdomyolysis |
6.0% |
| Drug Eruption |
4.0% |
| Haemolytic Anaemia |
4.0% |
| Hepatic Function Abnormal |
4.0% |
| Hepatitis Fulminant |
4.0% |
| Hypoglycaemic Coma |
4.0% |
| Interstitial Lung Disease |
4.0% |
| Red Blood Cell Count Decreased |
4.0% |
| Renal Impairment |
4.0% |
| Anaemia |
2.0% |
| Granulocytopenia |
2.0% |
| Hyperbilirubinaemia |
2.0% |
| Hypoglycaemia |
2.0% |
| Infection |
2.0% |
|
| Concomitant |
| Drug Use For Unknown Indication |
20.1% |
| Prophylaxis |
13.5% |
| Infection Prophylaxis |
8.0% |
| Diabetes Mellitus |
6.5% |
| Rectal Cancer |
5.9% |
| Product Used For Unknown Indication |
5.8% |
| Acquired Immunodeficiency Syndrome |
4.1% |
| Adult T-cell Lymphoma/leukaemia |
4.1% |
| Hypertension |
3.8% |
| Premedication |
3.6% |
| Pneumonia |
3.4% |
| Stem Cell Transplant |
3.0% |
| Pyrexia |
2.9% |
| Cancer Pain |
2.7% |
| Cardiac Failure |
2.6% |
| Liver Disorder |
2.5% |
| Prophylaxis Against Graft Versus Host Disease |
2.2% |
| Hiv Infection |
1.9% |
| Sepsis |
1.8% |
| Atypical Mycobacterial Infection |
1.7% |
|
| Renal Impairment |
10.3% |
| White Blood Cell Count Decreased |
9.4% |
| Nausea |
6.0% |
| Pneumonia |
6.0% |
| Stomatitis |
6.0% |
| Toxic Epidermal Necrolysis |
6.0% |
| Pulmonary Artery Thrombosis |
5.1% |
| Sepsis |
5.1% |
| Urinary Retention |
5.1% |
| Urinary Tract Infection |
5.1% |
| White Blood Cell Count Increased |
5.1% |
| Hyperbilirubinaemia |
4.3% |
| Respiratory Failure |
4.3% |
| Bone Marrow Failure |
3.4% |
| Febrile Neutropenia |
3.4% |
| Interstitial Lung Disease |
3.4% |
| Pyrexia |
3.4% |
| Thrombocytopenia |
3.4% |
| Memory Impairment |
2.6% |
| Pulmonary Alveolar Haemorrhage |
2.6% |
|
